Gastrointestinal Stromal Tumors – Etiology, Clinical Presentation and Review of the Literature in Greek Patients

Georgios Zacharis¹, Nada Zacharis², Nikiforos Rodis³, Charalampos Potsios⁴ and Panagiota Xaplanteri⁵*

¹General Hospital of Patras, Surgery Department, Patras, Greece.
²GP, Internal Medicine, Patras, Greece.
³Student in fifth year, Medical School, Democritus University of Thrace, Greece.
⁴University General Hospital of Patras, Department of Internal Medicine, Patras, Greece.
⁵School of Health Rehabilitation Sciences, Department of Nursing, University of Patras, Greece.

Correspondence:
Panagiota Xaplanteri, School of Health Rehabilitation Sciences, Department of Nursing, University of Patras, Greece, Tel: 0030-2261-036 9114, Fax: 0030-2610-322362.

Received: 09 May 2020; Accepted: 29 May 2020


ABSTRACT
Gastrointestinal stromal tumors (GIST) represent rare malignancies of mesenchymal origin that can appear at any site of the gastrointestinal tract. Their classification, patient treatment and prognosis had been a source of controversy. The biology of these tumors revealed association to the type III tyrosine kinase receptor and the KIT CD117 protein expression. GIST mesenchymal lesions derive from the interstitial cells of Cajal. Classification methods include the one by Miettinen and Lasota and the “modified NIH classification”. The treatment of choice is surgical intervention and complete removal of the neoplasm. In patients with tumors that cannot be excised, have given metastasis, or are of high risk for metastasis, treatment also involves Kit/PDGFRA tyrosine kinase inhibitors, such as imatinib. In Greece, several cases have been described.

Keywords
GIST, CD117, Imatinib.

Introduction
GISTs tumors are neoplasms of mesenchymal origin and represent 0.1-3% of all gastrointestinal tumors. Their most frequent sites of appearance are the stomach (60-70%), the small intestine (20-25%), the colon and rectum (5%) and the esophagus (<5%), although extraintestinal sites have also been described [1,2]. The term gastrointestinal stromal tumors (GIST) was firstly reported by Mazur and Clark in 1983 [3]. They used the term to characterize neoplasms of gastrointestinal tract origin that until then were falsely considered as smooth-muscle neoplasms [4]. Their classification and consequently differentiation, patient treatment and prognosis had been a source of controversy. At first they were proved to be CD34 positive, an immunopositivity related to origin of both spindle cell and epithelioid type cells. Later it proved that only 60-70% of GIST neoplasms were CD3 positive [3,4].

The biology of these tumors revealed that mutation associated to the type III tyrosine kinase receptor and the KIT CD117 protein expression play a significant role in their appearance. The expression of KIT protein (CD117) is recognized as a reliable phenotypic marker for these neoplasms [4-6]. GIST mesenchymal lesions derive from the interstitial cells of Cajal. These cells belong to the neuromuscular apparatus of the gastrointestinal tract. They have characteristics of both smooth muscle and neuronal cells and their role is to regulate peristalsis by generating intrinsic electrical rhythmicity [4,7]. Mutations in Kit juxtamembrane domain (exon 11) are the most common in GISTs of all sites, whereas rare Kit extracellular domain (exon 9) Ala502-Tyr503 duplication is specific for intestinal GISTs [8]. Mutations in plateletderived growth factor receptor alpha (PDGFRA) have also been described in juxtamembrane (exon 12) and tyrosine kinase domains (exons 14 and 18) in gastric GIST tumors of epithelioid origin [8]. Kit and PDGFRA genes encode for the homologous receptor tyrosine kinase proteins. Those proteins have structural characteristics of type III receptor tyrosine kinase family and regulate cellular
proliferation and apoptosis via phosphorylation. Mutations of KIT and PDGFRA permit increase in cellular proliferation and decrease the rate of apoptosis. As a result, these alterations and probably other genetic changes that follow, like loss of potential tumor suppressor genes in chromosome arms 14q and 22q, lead into the development of tumor [8].

GISTs usually occur in older adults (more than 60 years of age) and are equally distributed to both sexes. The most common symptom is bleeding of the gastrointestinal tract that can be acute or chronic and the patient presents with anemia. Other symptoms depend on the location of the tumor and include abdominal pain, nausea, vomiting, or bowel obstruction [6,8].

Physical examination and abdomen palpation are always the first steps to set diagnosis in combination with abdomen ultrasound [4]. In ultrasound the lesions appear as hypoechochogenic masses with cystic, necrotic or haemorrhagic features [9]. Computerized tomography (CT scan) confirms the appearance of tumor mass in the lower abdomen. [5]. CT scan without endovenous contrast reveals haemorrhage or calcification. After endovenous contrast the lesion shows heterogeneity [9]. MRI is useful in neoplasms located in the pelvic, mesenterium and peritoneum [9].

Histologically, the diagnosis of GIST falls into one of the following categories: spindle cell type (70%), epithelioid type (20%), or mixed type (10%) [4]. Histological diagnosis is usually performed via echoendoscopy-guided-biopsy or CT-guided percutaneous biopsy. For localized disease the treatment of choice is surgery and complete excision of the tumor [4].

The presence of epithelioid cells is related to malignancy. The size of the malignancy and the mitotic rate have been associated with the outcome. A tumor larger than 5 cm and with more than 5 mitoses per 50 high-power fields (HPF) is very likely to lead to metastasis and is also related to 40-50% of mortality [5,6]. In addition the location of the tumor has been described by many authors as a prognostic factor, but such a fact needs more elucidation and many risk classifications have been proposed [4].

GIST tumors with recurrence or hepatic metastasis are related to poor prognosis [4]. In the National Institutes of Health (NIH) classification tumor diameter and mitotic index are used. The risk-classification method by Miettinen and Lasota also includes the tumor location. The “modified NIH classification” in addition includes the term rupture of the tumor [10].

The treatment of choice is surgical intervention and complete removal of the neoplasm. In patients with tumors that cannot be excised, have given metastasis, or are of high risk for metastasis, treatment also involves Kit/PDGFRA tyrosine kinase inhibitors, such as imatinib [8]. The standard dosage for imatinib mesylate is 400 mg/day. The NCCN and ESMO guidelines recommend 800 mg/day for KIT exon 9mutated GISTs because of longer progression-free survival [10]. This therapy is not successful long term as resistance via secondary mutations or clonal selection is described [8,9]. Resistance to imatinib is considered primary when associated with progressive disease within 6 months, and secondary when associated with progressive disease after 6 months. Primary resistance relates to the D842V mutation and some KIT exon 9 mutations. Secondary resistance is related to therapy with imatinib and is due to new mutations in two kinase domains that occur in the ATP-binding pocket or activation loop. They are related to KIT exon 11 mutations and show clonal evolution [10]. In these patients sunitinib should be used and regorafenib for patients that neither imatinib nor sunitinib can be used [4,9].

In Greece, several cases of GIST have been described as case reports. GIST tumors originated from the jejunum have been described by Gourgiotis et al. (2009) Soufieris et al. (2008), Zacharis et al. (2017) [6,11,12]. GIST tumors of the duodenum have been reported by Germanos et al. (2011) [13]. GIST tumors of the ileum have been reported by Efremidou et al. (2006) [14]. GIST of colorectal origin have been described by Anagnostou et al. (2011). Dimitroulopoulos et al. (2009), Kalliouris et al. (2019) [5,15,16]. Two reports of exophytic Gastrointestinal Stromal Tumor of the Stomach have been reported by Kalliakmanis et al. (2017) [17]. A case of abdominal primary extra-gastrointestinal stromal tumor (E-GIST) has been described by Kalogeraki et al. (2015). Diagnosis was established by cytologic in ascitic fluid [18]. A case of an 80-year-old male with a simultaneous presentation of a gastric adenocarcinoma and GIST was presented by Theodosopoulos et al. (2011) [19]. In a prospective study 52 patients with GIST were analyzed by Tzilves et al. and the location of the tumors in descenting order were: stomach (51.9% of patients), small intestine (28.8%), colon and rectum (15.4%) and the esophagus in one patient [20]. In another prospective study 15 patients with GIST over a 6-year period (2005–2011) were reported by Koumarianou et al. Of those, with gastric origin were 66.6%, small intestine 13.3%, colon 13.3%, and retroperitoneal 6.6% [21].

GIST tumors although a rare entity, should always be in mind in the case of elderly patients with anemia, abdominal pain, nausea, vomiting, or bowel obstruction.

References


